Navigating the evolution of ophthalmic drug delivery and ocular regenerative medicine from conventional to cutting-edge treatments
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Retinal Development and Disorders · Corneal Surgery and Treatments · Retinal Diseases and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Intellective and stimuli-responsive drug delivery systems in eyes10.1016/j.ijpharm.2021.120591 ↗
2. Target strategies for drug delivery bypassing ocular barriers
3. Santos A, Altamirano-Vallejo JC, Navarro-Partida J, Gonzalez-de la Rosa A, Hsiao J. Breaking down the Barrier: Topical Liposomes as Nanocarriers for Drug Delivery into the Posterior Segment of the Eyeball. 2019.10.5772/intechopen.86601 ↗
4. Rupenthal ID. Depot formulations to sustain periocular drug delivery to the posterior eye segment10.1016/j.drudis.2019.03.023 ↗
5. Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases10.3390/pharmaceutics10010028 ↗
6. Nanoparticles for drug delivery to the anterior segment of the eye10.1016/j.addr.2017.04.001 ↗
7. A comprehensive review on contact lens for ophthalmic drug delivery10.1016/j.jconrel.2018.05.020 ↗
8. Topical drug delivery to the posterior segment of the eye: Thermodynamic considerations10.1016/j.ijpharm.2021.120332 ↗
9. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies10.1016/j.ijpharm.2021.120924 ↗
10. Challenges and strategies for the delivery of biologics to the cornea10.1016/j.jconrel.2021.04.008 ↗
11. Definition and Diagnostic Criteria of Dry Eye Disease: Historical Overview and Future Directions10.1167/iovs.17-23475 ↗
12. Triggering factors associated with a new episode of recurrent acute anterior uveitis10.1038/s41598-021-91701-6 ↗
13. Glaucoma and mortality risk: findings from a prospective population-based study10.1038/s41598-021-91194-3 ↗
14. 21st century glaucoma care
15. Ocular Drug Delivery: Present Innovations and Future Challenges10.1124/jpet.119.256933 ↗
16. Tuning of thermoresponsive pNIPAAm hydrogels for the topical retention of controlled release ocular therapeutics10.1039/C8TB02976H ↗
17. Nanoscale covalent organic frameworks: from controlled synthesis to cancer therapy10.1039/D1CC04846E ↗
18. Multifunctional Biomimetic Liposomes with Improved Tumor-Targeting for TNBC Treatment by Combination of Chemotherapy
19. Current advance of nanotechnology in diagnosis and treatment for malignant tumors10.1038/s41392-024-01889-y ↗
20. Nanomaterials for bone metastasis10.1016/j.jconrel.2024.07.067 ↗
21. Aptamer-functionalized liposomes for targeted cancer therapy10.1016/j.canlet.2019.01.045 ↗
22. Cholesterol-conjugated PEGylated PAMAM as an efficient nanocarrier for plasmid encoding interleukin-12 immunogene delivery toward colon cancer cells10.1002/btpr.2952 ↗
23. Recent advances in nanoparticle-based photothermal therapy for breast cancer10.1016/j.jconrel.2022.06.050 ↗
24. Current trends in stimuli-responsive nanotheranostics based on metal–organic frameworks for cancer therapy10.1016/j.mattod.2022.05.024 ↗
25. Platinum–Iron Nanoparticles for Oxygen-Enhanced Sonodynamic Tumor Cell Suppression10.3390/inorganics12120331 ↗
26. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer10.1016/j.ijpharm.2020.119513 ↗
27. Chitosan coated liposomes (CCL) containing Triamcinolone Acetonide for sustained Delivery: A Potential Topical Treatment for Posterior Segment Diseases
28. Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer10.2217/nnm-2022-0198 ↗
29. Shahidi M, Abazari O, Dayati P, Haghiralsadat BF, Oroojalian F, Tofighi D. Targeted delivery of 5-Fluorouracil, miR-532-3p and si-KRAS to colorectal tumor using Layer-by-Layer liposomes. 2022.10.21203/rs.3.rs-1692997/v1 ↗
30. Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy10.1002/jcp.26361 ↗
31. Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery
32. Docetaxel encapsulation in nanoscale assembly micelles of folate-PEG-docetaxel conjugates for targeted fighting against metastatic breast cancer in vitro and in vivo10.1016/j.ijpharm.2021.120822 ↗
33. Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics10.1016/j.jconrel.2022.06.026 ↗
34. Chapter 1 - Nanotechnology in the diagnosis of ocular diseases, drug delivery, and therapy: challenges and opportunities
35. Novel Ratiometric Surface-Enhanced Raman Scattering (SERS) Biosensor for Ultrasensitive Quantitative Monitoring of Human Carboxylesterase-1 in Hepatocellular Carcinoma Cells Using Ag–Au Nanoflowers as SERS Substrate10.1021/acs.analchem.4c04763 ↗
36. MOF derived core-shell CuO/C with temperature-controlled oxygen-vacancy for real time analysis of glucose10.1186/s12951-022-01715-z ↗
37. Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure10.3788/COL202018.051701 ↗
38. Multifunctional nanocomposite eye drops of cyclodextrin complex@layered double hydroxides for relay drug delivery to the posterior segment of the eye10.1016/j.carbpol.2021.117800 ↗
39. Expression, activity and pharmacokinetic impact of ocular transporters10.1016/j.addr.2017.12.009 ↗
40. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances10.1080/1061186X.2021.1878366 ↗
41. Multifunctional Nanocomposites Based on Liposomes and Layered Double Hydroxides Conjugated with Glycylsarcosine for Efficient Topical Drug Delivery to the Posterior Segment of the Eye10.1021/acs.molpharmaceut.8b01136 ↗
42. Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye10.1517/17425247.2016.1163334 ↗
43. Challenges and opportunities for drug delivery to the posterior of the eye10.1016/j.drudis.2019.05.035 ↗
44. Ocular Drug Delivery: A Special Focus on the Thermosensitive Approach10.3390/nano9060884 ↗
45. The PLGA microspheres synthesized by a thermosensitive hydrogel emulsifier for sustained release of risperidone
46. Preparation and in vitro evaluation of injectable formulations of levothyroxine sodium using in situ forming hydrogel temperature-responsive systems based on PLA-PEG-PLA and PLGA-PEG-PLGA triblock copolymers
47. Nanotechnology, and scaffold implantation for the effective repair of injured organs: An overview on hard tissue engineering10.1016/j.jconrel.2021.04.003 ↗
48. Chapter 6 - Thermoresponsive Drug Delivery Systems, Characterization and Application
49. Drug Delivery to the Posterior Segment of the Eye10.1159/000455276 ↗
50. PEG-based thermosensitive and biodegradable hydrogels10.1016/j.actbio.2021.04.009 ↗
51. A moldable thermosensitive hydroxypropyl chitin hydrogel for 3D cartilage regeneration in vitro and in vivo10.1016/j.actbio.2020.03.039 ↗
52. Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies10.1016/j.jconrel.2020.03.050 ↗
53. Functionalized Hyperbranched Polyethylenimines as Thermosensitive Drug Delivery Nanocarriers with Controlled Transition Temperatures10.1021/acs.biomac.7b01325 ↗
54. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond10.1016/j.drudis.2016.12.008 ↗
55. Newer Trends in In Situ Gelling Systems for Controlled Ocular Drug Delivery10.15406/japlr.2016.02.00022 ↗
56. Research progress of in-situ gelling ophthalmic drug delivery system10.1016/j.ajps.2018.04.008 ↗
57. An insight to ocular in situ gelling systems
58. Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: Recent progress and contemporary research10.3390/polym13081340 ↗
59. Advances and limitations of drug delivery systems formulated as eye drops10.1016/j.jconrel.2020.01.057 ↗
60. In situ gelling and mucoadhesive polymers: why do they need each other?10.1080/17425247.2018.1517741 ↗
61. Gel-based materials for ophthalmic drug delivery10.3390/gels7030130 ↗
62. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery10.1016/j.jconrel.2020.07.044 ↗
63. Ocular in situ gel: An overview10.22270/jddt.v9i1.2231 ↗
64. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide10.1016/j.ejps.2017.04.013 ↗
65. Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections10.1371/journal.pone.0248857 ↗
66. Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?10.1016/j.jconrel.2017.09.031 ↗
67. Formulation development and evaluation of Natamycin niosomal in-situ gel for ophthalmic drug delivery
68. A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole10.2147/IJN.S131850 ↗
69. An ex vivo evaluation of moxifloxacin nanostructured lipid carrier enriched in situ gel for transcorneal permeation on goat cornea10.1016/j.xphs.2019.04.005 ↗
70. Formulation of nanoparticles loaded in situ gel for treatment of dry eye disease: In vitro, ex vivo and in vivo evidences
71. Implications of the structure-property relationship on the optomechanical characterization of the cornea: A review
72. BCLA CLEAR-Anatomy and physiology of the anterior eye10.1016/j.clae.2021.02.009 ↗
73. Designing scaffolds for corneal regeneration10.1002/adfm.201908996 ↗
74. Regenerative medicine of cornea by cell sheet engineering using temperature-responsive culture surfaces10.1007/s11434-013-5742-1 ↗
75. Corneal tissue engineering: recent advances and future perspectives10.1089/ten.teb.2014.0397 ↗
76. Anatomy and physiology of the cornea10.1016/j.jcrs.2010.12.037 ↗
77. Karamichos · 2015 · 77
78. The triad of nanotechnology, cell signalling, and scaffold implantation for the successful repair of damaged organs: An overview on soft-tissue engineering10.1016/j.jconrel.2021.02.036 ↗
79. Scaffold-free and scaffold-based cellular strategies and opportunities for cornea tissue engineering10.1088/2516-1091/ac12d7 ↗
80. The progress in corneal translational medicine10.1039/D0BM01209B ↗
81. Design, clinical translation and immunological response of biomaterials in regenerative medicine10.1038/natrevmats.2016.40 ↗
82. Key players in the immune response to biomaterial scaffolds for regenerative medicine10.1016/j.addr.2017.07.006 ↗
83. Biocompatibility of Materials for Biomedical Engineering10.1007/978-981-15-3262-7_9 ↗
84. Biopolymer Hydrogel Scaffold as an Artificial Cell Niche for Mesenchymal Stem Cells10.3390/polym12112550 ↗
85. Cellular mechanotransduction10.3934/biophy.2016.1.50 ↗
86. Fabrication and characterization of platelet-rich plasma scaffolds for tissue engineering applications10.1016/j.msec.2016.10.001 ↗
87. Biocompatibility Evolves: Phenomenology to Toxicology to Regeneration10.1002/adhm.202002153 ↗
88. Clinical translation of tissue engineered products
89. Biocompatibility Study of Hydrogel Biopolymer Scaffold with Encapsulated Mesenchymal Stem Cells10.3390/polym15061337 ↗
90. PEG hydrogel degradation and the role of the surrounding tissue environment10.1002/term.1688 ↗
91. Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments10.1039/B816472J ↗
92. Bioengineering Approaches for Corneal Regenerative Medicine10.1007/s13770-020-00262-8 ↗
93. Effect of Corneal Nerve Ablation on Immune Tolerance Induced by Corneal Allografts, Oral Immunization, or Anterior Chamber Injection of Antigens10.1167/iovs.16-20601 ↗
94. Induction of Contrasuppressor Cells and Loss of Immune Privilege Produced by Corneal Nerve Ablation10.1167/iovs.18-24894 ↗
95. Scaffolds for drug delivery and tissue engineering: The role of genetics10.1016/j.jconrel.2023.05.042 ↗
96. The role of biomaterials and scaffolds in immune responses in regenerative medicine: macrophage phenotype modulation by biomaterial properties and scaffold architectures10.1039/D1BM00840D ↗
97. Biomaterials as Local Niches for Immunomodulation10.1021/acs.accounts.0c00341 ↗
98. Design Challenges in Polymeric Scaffolds for
99. Macroscale biomaterials strategies for local immunomodulation10.1038/s41578-019-0106-3 ↗
100. Pore-Forming Hydrogels for In Vivo Enrichment of Immature Dendritic Cells10.1002/adhm.201500618 ↗